Research Matters Blog

rss

Updates from MUSC's Offices of Research Administration


NIH Encourages Use of Preprints and Other Interim Research Products

A new notice from the NIH (Reporting Preprints and Other Interim Research Products, NOT-OD-17-050) indicates that interim research products, including preprints, can soon be cited where other research products are cited. This includes the NIH Biosketch and Section C of the Research Performance Progress Report (RPPR), among others. The change is effective for all applications submitted for the May 25, 2017 due date and beyond, and for RPPRs submitted on or after May 25, 2017.

  • The NIH encourages investigators to use interim research products but does not require their use.
  • Preprints do not apply under the NIH Public Access Policy.
  • This guide notice does not apply to clinical trial registration. See ClinicalTrials.gov about registration of clinical trial protocols.

What are Interim Research Products?

NIH defines interim research products as complete, public research products that are not final.  A common form is the preprint, which is a complete and public draft of a scientific document. Preprints are typically manuscripts written in the style of a peer-reviewed journal article that have not been subject to peer review. Scientists issue preprints to speed dissemination, establish priority, obtain feedback, and offset publication bias.

Citing Interim Research Products

When citing an interim research product, applicants and awardees must include the Digital Object Identifier and the Object type (e.g. preprint, protocol) in the citation. They should also list any information about the document version (e.g. most recent date modified), and if relevant, the date the product was cited.

Example:

Bar DZ, Atkatsh K, Tavarez U, Erdos MR, Gruenbaum Y, Collins FS. Biotinylation by antibody recognition- A novel method for proximity labeling. BioRxiv 069187 [Preprint]. August 11, 2016 [cited 2017 Jan 12].  Available from: https://doi.org/10.1101/069187.

For more information, see: NIH NOT-OD-17-050: Reporting Preprints and Other Interim Research Products.

Background

In October 2016, the NIH requested information on the use of interim research products and standards for reporting them (Request for information (RFI): Including Preprints and Interim Research Products in NIH Applications and Reports, NOT-OD-17-006). The NIH received 351 responses and nearly all respondents supported increasing the use of interim research products in NIH award processes. Specific benefits of interim research products include speeding dissemination of results, enhancing the rigor of the research and avoiding publication bias. For more information about the responses, see the Background and Public Comments section of: NIH NOT-OD-17-050: Reporting Preprints and Other Interim Research Products.


NIH Notice NOT-OD-17-049: FY2017 NIH Salary Cap - Interim Guidance

Per NIH notice NOT-OD-17-049, the new NIH salary cap is $187,000 effective January 8, 2017

Salaries up to this new $187,000 level are allowed to be charged starting January 8, 2017, to NIH funded grants provided the necessary funds are available.

NOTE: No additional funds will be provided by NIH.

Once the Department of Health and Human Services Appropriation for FY 2017 is enacted, NIH will publish the annual Notice of legislative mandates to provide information on any statutory provisions that limit the use of NIH grant funds in FY 2017.  Additional guidance on the salary cap will also be provided at that time. 

For those planning to make payroll adjustments due to this salary cap increase, we encourage using February 1st, 2017, as the start date for any changes.  Start dates other than the first day of the month may lead to errors due to the manual calculations required.

When preparing all future NIH grant proposals, please use the new salary cap maximum.  Both the ORSP Proposal Preparation page and Cayuse data are being updated to reflect the new NIH Salary Cap level.


eRA Commons Option Available to Submit an Unsolicited Application exceeding $500K in direct costs

NIH has a longstanding policy that states any applicant requesting $500,000 or more in direct costs (excluding consortium F&A costs) in any one budget period within a competitive segment is required to contact the NIH Institute or Center (IC) Program Official (PO), in writing or by telephone, as early as possible during development of the application but no later than 6 weeks before submission for prior approval. Since NIH supports projects with large budgets, the purpose of this policy is for fiscal planning and therefore it provides NIH ICs the appropriate amount of time to consider the possibility of such awards as early as possible in the budget and program planning process.

Notice number NOT-OD-17-005 informs NIH applicants that requests to submit an unsolicited application that will exceed $500,000 in direct costs will now have an option to submit this request electronically through eRA Commons, under a new Prior Approval Module.


Good Clinical Practice (GCP) training for faculty involved in NIH-funded clinical trials

National Institutes of Health announced that all NIH-funded clinical trials (whether its direct or pass-through) that will be active on or after January 1, 2017, investigators, and clinical trial staff(as defined) will need to complete Good Clinical Practice (GCP) training for NIH Awardees involved in NIH-funded Clinical Trials, and expectations for training. More information can be found here: NOT-OD-16-148.